Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CAR T-Cell Therapies Continue to Raise the Bar in Lymphoma Management

August 27th 2020

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Enzastaurin Combo Under Exploration in High-Risk, DGM1+ DLBCL

August 27th 2020

Investigators are evaluating the efficacy of enzastaurin, a PCKß inhibitor, in combination with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with high-risk DGM1–positive diffuse large B-cell lymphoma.

Asciminib Elicits Significant Major Molecular Responses in Ph+ Chronic-Phase CML

August 26th 2020

The novel investigational STAMP inhibitor asciminib significantly improved the major molecular response rate compared with bosutinib at 24 weeks in adult patients with Philadelphia chromosome–positive, chronic-phase chronic myeloid leukemia who received prior treatment with 2 or more TKIs.

Enasidenib Plus Best Supportive Care Misses OS End Point in Relapsed/Refractory IDH2+ AML

August 25th 2020

Enasidenib in combination with best supportive care failed to significantly improve overall survival in patients with relapsed/refractory acute myeloid leukemia whose tumors harbor an IDH2 mutation.

NCCN Guidelines Grant Tafasitamab Category 2A Designation in DLBCL

August 21st 2020

Tafasitamab has been added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

CLR 131 Leads to 100% Response Rate Among Patients With Relapsed/Refractory B-Cell Malignancies

August 21st 2020

The novel phospholipid-drug conjugate CLR 131 induced a 100% overall response rate in patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Dr. Chari on Investigational Belantamab Mafodotin Combos in Myeloma

August 20th 2020

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Dr. Sekeres on Staging Low- Versus High-Risk MDS

August 19th 2020

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Dr. Ghosh on Differences Among Available BTK Inhibitors in B-Cell Malignancies

August 18th 2020

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Dr. Pagel on Challenges With ASCT in Relapsed/Refractory DLBCL

August 18th 2020

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

August 18th 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Dr. Wong on the Potential Role of Venetoclax in Relapsed/Refractory AL Amyloidosis

August 18th 2020

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Tazemetostat Expands Follicular Lymphoma Tool Kit

August 18th 2020

The approval of tazemetostat has expanded the portfolio of treatment options for relapsed/refractory follicular lymphoma, a disease for which new agents are needed because patients do not uniformly derive benefit from available therapies.

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

August 14th 2020

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

August 14th 2020

Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.

Dr. Pagel on the Importance of Screening for Double- and Triple-Hit DLBCL

August 13th 2020

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

FDA Panel Supports Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD

August 13th 2020

The FDA’s Oncologic Drugs Advisory Committee voted 8 to 2 in favor of approving remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.

FDA Grants Umbralisib Priority Review for Previously Treated MZL

August 13th 2020

The FDA has granted a priority review designation to a new drug application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior anti-CD20–based treatment.

Dr. Nowakowski on Potential Clinical Implications of the ENGINE Study in DLBCL

August 12th 2020

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

August 11th 2020

Jennifer Woyach, MD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.